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EVALUATION OF THE PERSISTENCE OF DERIVATIZED
HYALURONIC ACID FOLLOWING INJECTION INTO THE
GUINEA PIG FEMOROPATELLAR FAT PAD TISSUES
S.M. Dethlefsen1, L-P. Yu1, N.M. Moran2, D.S. Garlick3,
E.M. Skrabut1
1Genzyme, Cambridge, MA; 2Genzyme, Framingham, MA;
3Charles River Laboratories, Worcester, MA
Purpose: Hyaluronan (HA) based viscosupplements are used to
reduce pain in patients with mild to moderate osteoarthritis. For
the patient to receive the full beneﬁt, these viscosupplements
must be injected directly into the joint space. Extra-articular
needle placement and injection of viscosupplements into the
subsynovial tissues may be linked to a higher incidence of
adverse reactions. In this study a guinea pig model was used
to investigate the cellular response to two viscosupplements,
non-animal stabilized hyaluronic acid (NASHA) and hylastan,
following injection into the fat pad to simulate misinjection of the
viscosupplement. These two crosslinked HA-based gels have
distinctly different rheological and physical properties. NASHA is
an epoxy crosslinked gel while hylastan is a non-animal HA gel
lightly crosslinked with divinyl sulfone.
Methods: Eighteen guinea pigs were randomized into two treat-
ment groups of 6 animals each and 1 HA control group (1% w/v
solution of unmodiﬁed HA) of 6 animals. Test or control material
was injected into the fat pad of the assigned animal. Fat pads in
the contra lateral joints were injected with lactated Ringer’s solu-
tion. Animals were sacriﬁced at 7 or 30 days following injection
and the fat pads ﬁxed in 4% paraformaldehyde for sectioning and
staining with hematoxylin and eosin (H&E). Some slides were
treated with hyaluronidase prior to staining with H&E to conﬁrm
the presence of HA-based material. The slides were examined
by a board certiﬁed veterinary pathologist for the presence of
residual HA-based material and cellular activity associated with
this material. Rheological properties were characterized by a
controlled stress rheometer and dynamic mechanical analysis.
Results: On day 7, residual HA-based material was observed
in tissues taken from both hylastan and NASHA-treated animals.
Test material was noted as a basophilic substance that formed
discrete clusters within the adipose tissue. The cellular response
to these two materials was characterized by the presence of
a thin layer of macrophages at the host-test material interface.
Macrophages appeared to easily inﬁltrate and degrade the mate-
rial in the hylastan-treated animals but not in the NASHA-treated
animals. No residual control material was present in tissues from
animals injected with the HA or lactated Ringer’s solution con-
trols. At day 30, residual hylastan was not observed in any of
the fat pad tissues. In contrast, residual NASHA was observed
as discrete aggregates of basophilic material associated with a
single layer of macrophages at the host material interface sur-
rounded by layers of ﬁbrous connective tissue that completely
encapsulated the material. Rheological measurements demon-
strate that hylastan is a softer, more cohesive gel than the
NASHA material.
Conclusions: We have evaluated the tissue distribution and
cellular activity of two HA-based test articles following injection
into the fat pads of guinea pigs. Microscopic analysis of the
cellular activity associated with the dissolution of hylastan was
quite different from that observed in tissue sections taken from
the NASHA-treated animals. Hylastan injected tissue demon-
strated a typical biomaterial response with macrophages that
are facilitating the resorption of implanted material at early time-
points. This inﬂammatory response resolves at later times once
the hylastan is completely resorbed. The NASHA injected tis-
sue demonstrated a similar early time response, but at the later
times showed a cellular and ﬁbrous encapsulation of the injected
material.
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ALPHA-2-MACROGLOBULIN INHIBITS THE
DEGRADATIVE ACTIVITIES OF ADAMTS-7 AND
ADAMTS-12
Y. Luan, D.R. Howell, K. Li, C. Liu
New York University, New York, NY
Purpose: We previously reported that ADAMTS-7 and ADAMTS-
12, two members of ADAMTS (a disintegrin and metalloprotease
with thrombospondin motifs) family, sharing the similar domain
organization in the family, degraded COMP in vitro and were
signiﬁcantly induced in the cartilage and synovium of arthritic
patients (Liu, et al, FASEB J. 2006; 20(7):988 and Liu, et al,
J. Biol. Chem. 2006; 281(23):15800). The purpose of this study
was to determine 1) whether cleavage activity of ADAMTS-
7 and -12 of COMP are associated with COMP degradation in
osteoarthritis; 2) whether a2M is a novel substrate for ADAMTS-7
and -12; and 3) whether a2M inhibits ADAMTS-7 or -12 cleavage
of COMP.
Methods: In vitro digestion assay of COMP by ADAMTS-7 and
ADAMTS-12; COMP degradation analyses in the cartilage of
OA patients; COMP degradation assay from the organ culturing
system in the presence of TNF-α with or without blocking anti-
bodies; COMP degradation assay from human chondrocytes in
which expressions of ADAMTS-7 or/and -12 were knock-down
by speciﬁc siRNA; Digestion of alpha-2-macroglobulin (a2M) by
ADAMTS-7 and -12 in vitro as well as the inhibition assays of
α2M on ADAMTS-7 or -12 digestion of COMP.
Results: The size of the COMP fragments produced by ei-
ther ADAMTS-7 or ADAMTS-12 is similar to that of COMP-
degradative fragments seen in OA patients; antibody blocking
assay indicated that speciﬁc antibodies against ADAMTS-7 or
ADAMTS-12 dramatically inhibits TNF-α-induced COMP degra-
dation in the cultured cartilage explants; and suppression of
ADAMTS-7 or ADAMTS-12 expression using siRNA silencing ap-
proach in the human chondrocytes also markedly prevents TNF-
α-induced COMP degradation. Both ADAMTS-7 and ADAMTS-
12 metalloproteinases were able to cleave α2M in a dose-
dependent manner, which gave rise to the cleavage products
with the molecular weights of 180 and 105 kDa respectively. Fur-
ther, α2M inhibits both ADAMTS-7- and ADAMTS-12-mediated
COMP degradation in a does-dependent manner.
Conclusions: Our observation demonstrated the importance
of COMP degradation by ADAMTS-7 and ADAMTS-12 in vivo;
furthermore, we revealed that α2-Macroglobulin (α2M) is a novel
substrate for ADAMTS-7 and ADAMTS-12. More signiﬁcantly,
α2M represents the ﬁrst endogenous inhibitor of ADAMTS-7 and
ADAMTS-12.
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EVIDENCE THAT THE NEUTRAL ACTIVE
HYALURONIDASE PH-20 CONTRIBUTES TO THE
BREAKDOWN OF CARTILAGE MATRIX IN HUMAN KNEE
OSTEOARTHRITIS
D.H. Manicourt, J-P. Devogelaer, J-E. Dubuc, C. Galant
Université Catholique de Louvain, Brussels, Belgium
Purpose: The discovery that chondrocytes, synoviocytes and
dermal ﬁbroblasts all produce a neutral active hyaluronidase sim-
ilar to the sperm or testicular hyaluronidase PH-20 might provide
new and important insights into mechanisms implicated during
embryogenesis and during the development of skin and joint
disorders. Therefore, we herein assessed the levels of PH-20 ex-
pression in human normal and osteoarthritic articular cartilage.
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Methods: Human knee articular cartilage with its subchondral
bone was either obtained from a tissue bank or sampled during
surgery for total knee joint replacement. Tissues were immedi-
ately processed for in situ hybridization and immunohistology.
Fluorescence intensity was semi-quantiﬁed and values obtained
for PH-20 were normalized by those obtained for cell DNA by us-
ing DAPI. The severity of the OA disease process was evaluated
by using the histologic-histochemical grading system devised by
Mankin.
Results: In normal cartilage PH-20 mRNA and PH-20 protein
were only detected in few chondrocytes of the superﬁcial car-
tilage layer as well as in few osteoclasts and osteoblasts of
the subchondral bone. As the severity of the OA disease pro-
cess increased, chondrocytes of middle and deeper cartilage
layers expressed the enzyme both at the mRNA and protein
levels. Scores of the Mankin’s scale correlated signiﬁcantly with
the level of PH-20 expression as assessed by ﬂuorescence in-
tensity. The enzyme was also detected outside cartilage cells
mostly in areas exhibiting erosions and in areas surrounding
clefts. In specimens with moderate to severe OA lesions, one
could also detect the enzyme signal in subchondral bone and
in some connective tissues cells ﬁlling up the spaces between
bone trabeculae.
Conclusions: Our data provide evidence that the PH-20 pro-
duced by chondrocytes might be implicated in the degradation
of cartilage matrix during OA. Indeed, the enzyme not only de-
grades hyaluronan, the backbone of aggrecan aggrecates and
a backbone of the pericullar matrix, but also chondroitin sul-
fate chains. Our data also suggest that, in OA, other cell lines
present in subchondral bone areas might contribute to the local
production of PH-20.
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SELECTIVE INHIBITION OF AGGRECANASE PREVENTS
AGGRECAN DEGRADATION AND PROMOTES
INCORPORATION OF NEWLY SYNTHESIZED AGGRECAN
INTO THE EXTRACELLULAR MATRIX OF HUMAN
OSTEOARTHRITIC CARTILAGE
P.S. Chockalingam, C. Keohan, R. Sheldon, P-E. Sum,
J. Sabatini, M.K. Majumdar, K.E. Georgiadis, E.A. Morris
Wyeth Research, Cambridge, MA
Purpose: Depletion of aggrecan is one of the earliest changes
observed in osteoarthritis (OA). Aggrecan is a chondroitin sulfate
and keratan sulfate-bearing proteoglycan. Aggrecan cleavage
by Aggrecanase results in the release of a large sulfated gly-
cosaminoglycan (sGAG)-containing aggrecan fragments which
diffuse out of the cartilage matrix. Inhibiting Aggrecanase activity
is an attractive therapeutic target. The purpose of this study was
to understand the effects of a selective Aggrecanase inhibitor on
the fate of existing and newly synthesized proteoglycan in human
osteoarthritic articular cartilage.
Methods: Human cartilage from total knee replacements har-
vested within 3 hours of surgery was used for this study (n=3
donors). Harvested cartilage was maintained in culture in the
presence or absence of a selective Aggrecanase inhibitor. Total
proteoglycan content of conditioned media or cartilage matrix
was measured as sGAG by a colorimetric assay with dimethyl-
methylene blue. Aggrecan released from the cartilage was fur-
ther characterized using a monoclonal antibody (BC-3) that rec-
ognizes the neoepitope generated by Aggrecanase-mediated
cleavage of aggrecan. Articular cartilage was cultured in the
presence of [35S]sulfate to enable localization and characteriza-
tion of newly synthesized aggrecan.
Results: Human osteoarthritic articular cartilage from joints un-
dergoing total knee replacement demonstrated signiﬁcant, on-
going aggrecanase activity evidenced by release of aggrecan
cleaved at the “aggrecanase cleavage site” (G373-374A). Incu-
bation in the presence of the selective Aggrecanase inhibitor
reduced total proteoglycan loss. Cleavage of newly synthesized
aggrecan was a signiﬁcant component of the degradative pro-
cess, and Aggrecanase inhibition resulted in increased incorpo-
ration of new proteoglycan into the cartilage matrix.
Conclusions: Aggrecanase activity is a characteristic of hu-
man osteoarthritis throughout the disease process. Inhibition
of Aggrecanase activity reduced release of aggrecan degrada-
tion products from the articular cartilage matrix. Because newly
synthesized aggrecan appeared to be especially susceptible to
degradation by Aggrecanases, selective Aggrecanase inhibition
resulted in a net increase in proteoglycan incorporation into the
matrix of human osteoarthritic cartilage. These results indicate
that inhibition of Aggrecanases will reduce aggrecan degrada-
tion in human osteoarthritric articular cartilage throughout the
disease process, and may also result in a net increase in extra-
cellular matrix proteoglycan.
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STIMULATING CARTILAGE OLIGOMERIC MATRIX
PROTEIN PRODUCTION IN CARTILAGE REGENERATION
Y.M. Bastiaansen-Jenniskens1, W. Koevoet1, J.A. Verhaar1,
G.J. van Osch1, J. DeGroot2
1Erasmus MC, University Medical Center, Rotterdam, The
Netherlands; 2Business Unit BioSciences, TNO Quality of Life,
Leiden, The Netherlands
Purpose: Cartilage Oligomeric Matrix Protein (COMP) is a pro-
tein present in the cartilage matrix. It binds to chondrocytes
and collagen and is involved in interaction between chondro-
cytes and collagen and probably also in collagen ﬁbrillogenesis.
COMP is expressed more abundantly in OA cartilage than in
normal healthy cartilage. The present study was designed to
investigate the effect of growth factors on COMP deposition and
the inﬂuence of COMP on collagen deposition and mechanical
properties.
Methods: Bovine chondrocytes in alginate beads were cultured
with or without 25 ng/ml IGF1, TGFbeta2 or FGF2. COMP gene
expression was determined with quantitative RT-PCR. COMP
protein production was determined with ELISA and Western blot
(reducing and non-reducing). Human COMP (hCOMP) was also
overexpressed in bovine chondrocytes using lentiviral transfec-
tion. hCOMP gene expression, COMP, collagen and proteoglycan
deposition and mechanical properties were determined.
Results: Addition of TGFbeta2 resulted in more COMP gene
expression than the control condition without growth factors or
with addition of IGF1. The COMP deposition in alginate beads
and excretion in the culture medium was also increased with ad-
dition of TGFbeta2. FGF2 resulted in less and partially degraded
COMP. Lentiviral transfection with hCOMP resulted in elevated
gene expression of hCOMP and increased COMP levels in the
culture medium compared to untransfected cells. However, no
difference was seen in the COMP deposition in the alginate
bead. COMP overexpression also did not affect the deposition of
collagen and proteoglycans or the mechanical properties.
Conclusions: It appears that COMP overexpression is not suf-
ﬁcient to increase extracellular COMP deposition in chondrocyte
alginate culture. However, increased COMP deposition can be
achieved by addition of TGFbeta, suggesting that modiﬁcation of
other factors such as collagen type IX or matrillins is also needed
to increase COMP deposition in cartilage regeneration.
